Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

Jawed Fareed, Debra Hoppensteadt, Josephine Cunanan, Walter Jeske, Ph.D., Cafer Adiguzal, He Zhu, MD, Cinara Echart, Massimo Iacobelli

Blood (2009) 114 (22): 4180.

https://doi.org/10.1182/blood.V114.22.4180.4180

Published: 2009

Journal Articles

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

Luba Benimetskaya, Sijian Wu, Anatoliy M. Voskresenskiy, Cinara Echart, Jin-Feng Zhou, Joongho Shin, Massimo Iacobelli, Paul Richardson, Kanyalakshmi Ayyanar, C. A. Stein

Blood (2008) 112 (10): 4343–4352.

https://doi.org/10.1182/blood-2008-04-149682

Published: 2008

Journal Articles

Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.

Cinara Echart, PhD, Cinzia Repice, Laura Ferro, MD, Kenneth Anderson, MD, Paul Richardson, MD, Anna Falanga, MD, Jawed Fareed, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 1992.

https://doi.org/10.1182/blood.V110.11.1992.1992

Published: 2007

Journal Articles

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Cinara Echart, PhD, Barbara Graziadio, Cinzia Repice, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2502.

https://doi.org/10.1182/blood.V110.11.2502.2502

Published: 2007

Journal Articles

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Cinara Echart, PhD, Maria Distaso, Laura Ferro, MD, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2513.

https://doi.org/10.1182/blood.V110.11.2513.2513

Published: 2007

Journal Articles

Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.

Constantine S. Mitsiades, Luba Benimetskaya, Krishna Menon, Cinara Echart, Cecile Rouleau, Beverly Teicher, Antonio Palumbo, Mario Boccadoro, Massimo Iacobelli, Kenneth C. Anderson, Cy A. Stein, Paul G. Richardson

Blood (2006) 108 (11): 3523.

https://doi.org/10.1182/blood.V108.11.3523.3523

Published: 2006

NARROW

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.

Email alerts

ASH Publications

American Society of Hematology

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only